A Phase 3 interventional study of Cisplatin and Oxaliplatin in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by BeiGene. Completed at 124 sites in 16 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-07-29.
Sponsored by BeiGene · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 23 studies testing tislelizumab in Esophageal Squamous Cell Carcinoma — 13 open to participants now, 15 under way, 1 of them phase 3. tislelizumab · Esophageal Squamous Cell Carcinoma.
Among the 23 studies testing tislelizumab in Esophageal Squamous Cell Carcinoma, this one has the largest enrollment, is one of 2 that started in 2018, is one of 3 in phase 3, and was the 2nd registered.
678 studies on the registry are indexed under Esophageal Squamous Cell Carcinoma; 269 are open to participants now.
Browse Esophageal Squamous Cell Carcinoma studies →13 of the 23 studies testing tislelizumab in Esophageal Squamous Cell Carcinoma are open now, in 4 countries. Recruiting first, the newest first:
BeOne Medicines · Sites in Japan
Ages 18+
BeOne Medicines · Sites in United States
Ages 18+
Ming-Yu Lien · Sites in Taiwan
Ages 20+
Shanghai Zhongshan Hospital · Sites in China
Ages 18+
Sichuan University · Sites in China
Ages 18–75
By country, each count listing its studies:
tislelizumab: first FDA approval 2024 (TEVIMBRA), first EMA approval 2023. What it is approved for, and how studies give it, is on its page →
Of the 180 Esophageal Squamous Cell Carcinoma studies recruiting now, 83 (46%) set no upper age limit and 76 (42%) stop at 75 or younger; 3 take children under 18; 8 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
23 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 17 · Phase 3 4 · Phase 4 1
First in 2018; this study’s year is marked. 2 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 649 is above the median of 64 across 564 interventional studies indexed under Esophageal Squamous Cell Carcinoma.
Median enrollment 50 across the 23 interventional studies. Of the 6 that completed or were terminated, 5 (83%) have results posted.
This tab as a report to print or save as PDF → With an account.
7 of 23 have an industry lead sponsor. The 10 most frequent:
This study is registered under BeiGene, one of the names counted as BeOne Medicines. Under that name alone:
BeiGene is the lead sponsor of 125 studies on the registry; 2 are open to participants now.
Of its 55 completed or terminated interventional studies of FDA-regulated products, 32 (58%) have results posted.
10 studies in Esophageal Squamous Cell Carcinoma by BeOne Medicines: 2 open now, 2 under way, none of them phase 3. Of 8 finished, 6 (75%) have results posted.
Among the 10 studies in Esophageal Squamous Cell Carcinoma by BeOne Medicines, this one has the largest enrollment, is one of 2 that started in 2018, is one of 3 in phase 3, and was the 3rd registered.
BeOne Medicines’s Esophageal Squamous Cell Carcinoma studies by the year they started, since 2017.
1 of the studies testing tislelizumab in Esophageal Squamous Cell Carcinoma that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07317609Shanghai Zhongshan HospitalNeoadjuvant Immunotherapy Combined With Chemotherapy Sequenced With Endoscopic Resection for Esophageal Cancer (Endosurgery-02) | 2027-09-30 |
Add it to your calendar (.ics) → With an account.
Among the 23 studies testing tislelizumab in Esophageal Squamous Cell Carcinoma, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among BeOne Medicines’s 10 in Esophageal Squamous Cell Carcinoma:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the efficacy and safety of tislelizumab as first line treatment in combination with chemotherapy in participants with advanced unresectable/metastatic esophageal squamous cell carcinoma (ESCC).
Key Inclusion Criteria:
Key Exclusion Criteria:
NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PD-1, PD-L1 and checkpoint inhibitors
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received tislelizumab 200 milligrams (mg) administered intravenously (IV) on Day 1 of each 3-week treatment cycle together with an investigator-chosen chemotherapy doublet until unacceptable toxicity, disease progression or withdrawal for other reasons. Chemotherapy options were a platinum agent (cisplatin 60-80 mg/m² intravenously on Day 1 or oxaliplatin 130 mg/m² intravenously on Day 1) combined with a fluoropyrimidine (fluorouracil \[750-800 mg/m² intravenously on Days 1-5\] or capecitabine \[1000 mg/m² orally twice daily on Days 1-14\]) or paclitaxel (175 mg/m² intravenously on Day 1).
Drug: Cisplatin · Drug: Oxaliplatin · Drug: Fluorouracil (5-FU) · Drug: Capecitabine · Drug: Paclitaxel · Biological: Tislelizumab
Participants received placebo administered IV on Day 1 of each 3-week treatment cycle together with an investigator-chosen chemotherapy doublet until unacceptable toxicity, disease progression or withdrawal for other reasons. Chemotherapy options were a platinum agent (cisplatin 60-80 mg/m² intravenously on Day 1 or oxaliplatin 130 mg/m² intravenously on Day 1) combined with a fluoropyrimidine (fluorouracil \[750-800 mg/m² intravenously on Days 1-5\] or capecitabine \[1000 mg/m² orally twice daily on Days 1-14\]) or paclitaxel (175 mg/m² intravenously on Day 1).
Drug: Cisplatin · Drug: Oxaliplatin · Drug: Fluorouracil (5-FU) · Drug: Capecitabine · Drug: Paclitaxel · Drug: Placebo
Cisplatin 60-80 mg/m² administered by intravenous infusion every 3 weeks. Cisplatin was used as the platinum agent in China, Taiwan, and Japan.
Oxaliplatin 130 mg/m² administered by intravenous infusion every 3 weeks.
Fluorouracil 750-800 mg/m² administered by intravenous infusion on Days 1-5 of each treatment cycle.
Capecitabine 1000 mg/m² administered orally twice daily on Days 1-14 of each treatment cycle
Paclitaxel 175 mg/m² administered by intravenous infusion every 3 weeks.
Tislelizumab 200 mg administered by intravenous infusion every 3 weeks.
Also known as: BGB-A317, TEVIMBRA
Placebo to match tislelizumab administered by intravenous infusion every 3 weeks.
Overall Survival (OS)
Overall survival is defined as the time from the date of randomization until the date of death due to any cause. Median OS was estimated using the Kaplan-Meier method. Primary analysis (data cut-off date of 28 February 2022) was the pre-defined analysis at which the primary endpoint was tested for superiority.
Time frame: From randomization to the primary analysis cutoff date of 28 February 2022; maximum time on follow-up was 3 years and 2 months.
Progression-Free Survival (PFS)
Progression-free survival is defined as the time from the date of randomization to the date of first documentation of disease progression assessed by the investigator per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1, or death, whichever occurred first. Median PFS was estimated using the Kaplan-Meier method. Progressive disease is defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study, and an absolute increase of at least 5 mm, or unequivocal progression of existing nontarget lesions, or the appearance of 1 or more new lesions. Primary analysis (data cut-off date of 28 February 2022) was the pre-defined analysis at which the primary endpoint was tested for superiority. Testing for all secondary efficacy endpoints was conducted at the time of the primary analysis.
Time frame: From randomization to the primary analysis cutoff date of 28 February 2022; maximum time on follow-up was 3 years and 2 months.
Objective Response Rate (ORR)
ORR is defined as the percentage of participants whose best overall response (BOR) was complete response (CR) or partial response (PR) assessed by the investigator per RECIST v1.1. Tumor assessments included computed tomography (CT) scans or magnetic resonance imaging (MRI), with preference for CT, of the neck, chest, and abdomen. CR: Disappearance of all target and nontarget lesions with no new lesions. Any pathological lymph nodes (whether target or nontarget) must have reduction in short axis to \< 10 mm. PR: Disappearance of all target lesions with persistence of 1 or more nontarget lesion(s), no new lesions, and/or maintenance of tumor marker level above the normal limits, or, at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Testing for all secondary efficacy endpoints was conducted at the time of the primary analysis (data cutoff date of 28 February 2022).
Time frame: Response was assessed every 6 weeks for the first 48 weeks, then every 9 weeks thereafter; up to the primary analysis cutoff date of 28 February 2022; maximum time on follow-up was 3 years and 2 months.
Overall Survival (OS) in Participants With a PD-L1 Score ≥ 10%
OS is defined as the time from the date of randomization until the date of death due to any cause. Median OS was estimated using the Kaplan-Meier method. Primary analysis (data cut-off date of 28 February 2022) was the pre-defined analysis at which the primary endpoint was tested for superiority. Testing for all secondary efficacy endpoints was conducted at the time of the primary analysis.
Time frame: From randomization to the primary analysis cutoff date of 28 February 2022; maximum time on follow-up was 3 years and 2 months.
Duration of Response (DOR)
DOR is defined as the time from the first determination of an objective response until the first documentation of progression assessed by the investigator per RECIST v1.1 or death, whichever occurred first. Median DOR was estimated using the Kaplan-Meier method. Primary analysis (data cut-off date of 28 February 2022) was the pre-defined analysis at which the primary endpoint was tested for superiority. Testing for all secondary efficacy endpoints was conducted at the time of the primary analysis.
Time frame: From randomization to the primary analysis cutoff date of 28 February 2022; maximum time on follow-up was 3 years and 2 months.
Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire - Oesophageal Cancer 18 Question Module (QLQ-OES18) Dysphagia, Eating, Reflux, Pain, and Index Scores
The EORTC-QLQ-OES18 is the specific esophageal symptoms module of the QLQ-C30. QLQ-OES18 is comprised of 18 questions grouped into 4 multi-item subscales: Dysphagia (3 items), Eating (4 items), Reflux (2 items), and Pain (3 items) and 6 single item subscales (trouble swallowing saliva, choking, dry mouth, taste, coughing, and talking). Participants indicate the extent to which they have experienced symptoms on a scale from 1 (Not at all) to 4 (Very much). Scores are calculated as the average of the items that contribute to the scale, then transformed to a scale from 0 to 100. The OES18 index score is calculated as the average of the 4 multi-item subscales and 6 single-item subscales. Higher scores indicate a higher level of symptomatology or problems.
Time frame: Baseline, Cycle 6 (Week 15)
Change From Baseline in European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire - Core 30 (QLQ-C30) Global Health Status/Quality of Life (GHS/QoL) and Physical Functioning Scales
The EORTC QLQ-30 contains 30 questions that incorporate 5 functional scales (physical functioning, role functioning, emotional functioning, cognitive functioning, and social functioning), 1 global health status scale, 3 symptom scales (fatigue, nausea and vomiting, and pain), and 6 single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). The participant answers questions about their health during the past week. There are 28 questions answered on a 4-point scale where 1 = Not at all (best) and 4 = Very Much (worst) and 2 global health quality of life (QOL) questions answered on a 7-point scale where 1 = Very poor and 7 = Excellent. Raw scores are transformed to a 0 to 100 scale via linear transformation. Higher scores in GHS and functional scales indicate better quality of life.
Time frame: Baseline, Cycle 6 (Week 15)
Change From Baseline in EORTC QLQ-C30 Fatigue Scale
The EORTC QLQ-30 contains 30 questions that incorporate 5 functional scales (physical functioning, role functioning, emotional functioning, cognitive functioning, and social functioning), 1 global health status scale, 3 symptom scales (fatigue, nausea and vomiting, and pain), and 6 single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). The participant answers questions about their health during the past week. There are 28 questions answered on a 4-point scale where 1 = Not at all (best) and 4 = Very Much (worst) and 2 global health quality of life (QOL) questions answered on a 7-point scale where 1 = Very poor and 7 = Excellent. Raw scores are transformed to a 0 to 100 scale via linear transformation. The fatigue symptom scale includes 3 items and ranges from 0 to 100, where higher scores indicate a higher level of symptoms.
Time frame: Baseline, Cycle 6 (Week 15)
Change From Baseline in European Quality of Life 5-Dimension 5-Level (EQ-5D-5L) Visual Analog Scale (VAS)
The EQ-5D-5L measures health outcomes using a VAS to record a participant's self-rated health on a scale from 0 to 100, where 100 is 'the best health you can imagine' and 0 is 'the worst health you can imagine.' A higher score indicates better health outcomes.
Time frame: Baseline, Cycle 6 (Week 15)
Number of Participants Experiencing Treatment-emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)
An AE is defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study drugs, whether related to study drugs or not. An SAE is any untoward medical occurrence that, at any dose met any of the following criteria: * Resulted in death * Was life-threatening * Required hospitalization or prolongation of existing hospitalization * Resulted in disability/incapacity * Was a congenital anomaly/birth defect * Was considered a significant medical AE by the Investigator based on medical judgement.
Time frame: From first dose of study drug up to 30 days after last dose; maximum time on treatment was 63.5 months.
This study was conducted at 162 centers in 16 countries/regions across Asia, Europe, North America, and Oceania.
| Milestone | Tislelizumab + Chemotherapy | Placebo + Chemotherapy |
|---|---|---|
| Started | 326 | 323 |
| Treated | 324 | 321 |
| Completed | 0 | 0 |
| Not completed | 326 | 323 |
| Withdrew: Death | 252 | 268 |
| Withdrew: Withdrawal by subject | 19 | 21 |
| Withdrew: Lost to follow-up | 7 | 6 |
| Withdrew: Sponsor ended study | 48 | 28 |
Overall survival is defined as the time from the date of randomization until the date of death due to any cause. Median OS was estimated using the Kaplan-Meier method. Primary analysis (data cut-off date of 28 February 2022) was the pre-defined analysis at which the primary endpoint was tested for superiority.
| months | Tislelizumab + Chemotherapy | Placebo + Chemotherapy |
|---|---|---|
| Overall Survival (OS) | 17.2 (15.8 to 20.1) | 10.6 (9.3 to 12.1) |
Progression-free survival is defined as the time from the date of randomization to the date of first documentation of disease progression assessed by the investigator per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1, or death, whichever occurred first. Median PFS was estimated using the Kaplan-Meier method. Progressive disease is defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study, and an absolute increase of at least 5 mm, or unequivocal progression of existing nontarget lesions, or the appearance of 1 or more new lesions. Primary analysis (data cut-off date of 28 February 2022) was the pre-defined analysis at which the primary endpoint was tested for superiority. Testing for all secondary efficacy endpoints was conducted at the time of the primary analysis.
| months | Tislelizumab + Chemotherapy | Placebo + Chemotherapy |
|---|---|---|
| Progression-Free Survival (PFS) | 7.3 (6.9 to 8.3) | 5.6 (4.9 to 6.0) |
ORR is defined as the percentage of participants whose best overall response (BOR) was complete response (CR) or partial response (PR) assessed by the investigator per RECIST v1.1. Tumor assessments included computed tomography (CT) scans or magnetic resonance imaging (MRI), with preference for CT, of the neck, chest, and abdomen. CR: Disappearance of all target and nontarget lesions with no new lesions. Any pathological lymph nodes (whether target or nontarget) must have reduction in short axis to \< 10 mm. PR: Disappearance of all target lesions with persistence of 1 or more nontarget lesion(s), no new lesions, and/or maintenance of tumor marker level above the normal limits, or, at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Testing for all secondary efficacy endpoints was conducted at the time of the primary analysis (data cutoff date of 28 February 2022).
| percentage of participants | Tislelizumab + Chemotherapy | Placebo + Chemotherapy |
|---|---|---|
| Objective Response Rate (ORR) | 63.5 (58.0 to 68.7) | 42.4 (37.0 to 48.0) |
OS is defined as the time from the date of randomization until the date of death due to any cause. Median OS was estimated using the Kaplan-Meier method. Primary analysis (data cut-off date of 28 February 2022) was the pre-defined analysis at which the primary endpoint was tested for superiority. Testing for all secondary efficacy endpoints was conducted at the time of the primary analysis.
| months | Tislelizumab + Chemotherapy | Placebo + Chemotherapy |
|---|---|---|
| Overall Survival (OS) in Participants With a PD-L1 Score ≥ 10% | 16.6 (15.3 to 24.4) | 10.0 (8.6 to 13.3) |
DOR is defined as the time from the first determination of an objective response until the first documentation of progression assessed by the investigator per RECIST v1.1 or death, whichever occurred first. Median DOR was estimated using the Kaplan-Meier method. Primary analysis (data cut-off date of 28 February 2022) was the pre-defined analysis at which the primary endpoint was tested for superiority. Testing for all secondary efficacy endpoints was conducted at the time of the primary analysis.
| months | Tislelizumab + Chemotherapy | Placebo + Chemotherapy |
|---|---|---|
| Duration of Response (DOR) | 7.1 (6.1 to 8.1) | 5.7 (4.4 to 7.1) |
The EORTC-QLQ-OES18 is the specific esophageal symptoms module of the QLQ-C30. QLQ-OES18 is comprised of 18 questions grouped into 4 multi-item subscales: Dysphagia (3 items), Eating (4 items), Reflux (2 items), and Pain (3 items) and 6 single item subscales (trouble swallowing saliva, choking, dry mouth, taste, coughing, and talking). Participants indicate the extent to which they have experienced symptoms on a scale from 1 (Not at all) to 4 (Very much). Scores are calculated as the average of the items that contribute to the scale, then transformed to a scale from 0 to 100. The OES18 index score is calculated as the average of the 4 multi-item subscales and 6 single-item subscales. Higher scores indicate a higher level of symptomatology or problems.
| score on a scale | Tislelizumab + Chemotherapy | Placebo + Chemotherapy |
|---|---|---|
| Dysphagia | -0.5 (-4.7 to 3.7) | -4.9 (-9.4 to -0.5) |
| Eating | -0.9 (-3.1 to 1.3) | -1.5 (-3.8 to 0.9) |
| Reflux | -1.3 (-3.2 to 0.7) | 0.2 (-1.9 to 2.2) |
| Pain | -5.2 (-6.7 to -3.7) | -3.3 (-4.9 to -1.8) |
| Index Score | -1.0 (-2.2 to 0.3) | -0.6 (-1.9 to 0.7) |
The EORTC QLQ-30 contains 30 questions that incorporate 5 functional scales (physical functioning, role functioning, emotional functioning, cognitive functioning, and social functioning), 1 global health status scale, 3 symptom scales (fatigue, nausea and vomiting, and pain), and 6 single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). The participant answers questions about their health during the past week. There are 28 questions answered on a 4-point scale where 1 = Not at all (best) and 4 = Very Much (worst) and 2 global health quality of life (QOL) questions answered on a 7-point scale where 1 = Very poor and 7 = Excellent. Raw scores are transformed to a 0 to 100 scale via linear transformation. Higher scores in GHS and functional scales indicate better quality of life.
| score on a scale | Tislelizumab + Chemotherapy | Placebo + Chemotherapy |
|---|---|---|
| Global Health Status/ QOL | -0.3 (-2.3 to 1.8) | -3.6 (-5.8 to -1.4) |
| Physical Functioning | -4.8 (-6.6 to -3.0) | -7.3 (-9.2 to -5.4) |
The EORTC QLQ-30 contains 30 questions that incorporate 5 functional scales (physical functioning, role functioning, emotional functioning, cognitive functioning, and social functioning), 1 global health status scale, 3 symptom scales (fatigue, nausea and vomiting, and pain), and 6 single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). The participant answers questions about their health during the past week. There are 28 questions answered on a 4-point scale where 1 = Not at all (best) and 4 = Very Much (worst) and 2 global health quality of life (QOL) questions answered on a 7-point scale where 1 = Very poor and 7 = Excellent. Raw scores are transformed to a 0 to 100 scale via linear transformation. The fatigue symptom scale includes 3 items and ranges from 0 to 100, where higher scores indicate a higher level of symptoms.
| score on a scale | Tislelizumab + Chemotherapy | Placebo + Chemotherapy |
|---|---|---|
| Change From Baseline in EORTC QLQ-C30 Fatigue Scale | 8.0 (5.7 to 10.4) | 9.4 (6.9 to 11.9) |
The EQ-5D-5L measures health outcomes using a VAS to record a participant's self-rated health on a scale from 0 to 100, where 100 is 'the best health you can imagine' and 0 is 'the worst health you can imagine.' A higher score indicates better health outcomes.
| score on a scale | Tislelizumab + Chemotherapy | Placebo + Chemotherapy |
|---|---|---|
| Change From Baseline in European Quality of Life 5-Dimension 5-Level (EQ-5D-5L) Visual Analog Scale (VAS) | -1.1 ± 15.82 | -3.1 ± 14.01 |
An AE is defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study drugs, whether related to study drugs or not. An SAE is any untoward medical occurrence that, at any dose met any of the following criteria: * Resulted in death * Was life-threatening * Required hospitalization or prolongation of existing hospitalization * Resulted in disability/incapacity * Was a congenital anomaly/birth defect * Was considered a significant medical AE by the Investigator based on medical judgement.
| Participants | Tislelizumab + Chemotherapy | Placebo + Chemotherapy |
|---|---|---|
| Treatment-emergent adverse event | 323 | 319 |
| Serious adverse events | 160 | 128 |
Collected over All-cause mortality was assessed from randomization until the end of study, maximum time on study was 63.6 months. Adverse events were assessed from first dose of study drug to 30 days after last dose, maximum time on treatment was 63.5 months.. Non-serious events are listed at a 3% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Tislelizumab + Chemotherapy | 252/326 (77.3%) | 160/324 (49.4%) | 321/324 (99.1%) |
| Placebo + Chemotherapy | 268/323 (83%) | 128/321 (39.9%) | 314/321 (97.8%) |
| Event | Tislelizumab + Chemotherapy | Placebo + Chemotherapy |
|---|---|---|
| PneumoniaInfections and infestations | 19/324 | 23/321 |
| DysphagiaGastrointestinal disorders | 17/324 | 8/321 |
| NeutropeniaBlood and lymphatic system disorders | 1/324 | 7/321 |
| DiarrhoeaGastrointestinal disorders | 7/324 | 3/321 |
| Oesophageal stenosisGastrointestinal disorders | 7/324 | 2/321 |
| VomitingGastrointestinal disorders | 7/324 | 5/321 |
| AnaemiaBlood and lymphatic system disorders | 6/324 | 6/321 |
| General physical health deteriorationGeneral disorders | 6/324 | 4/321 |
| Decreased appetiteMetabolism and nutrition disorders | 6/324 | 2/321 |
| HyponatraemiaMetabolism and nutrition disorders | 6/324 | 2/321 |
| Event | Tislelizumab + Chemotherapy | Placebo + Chemotherapy |
|---|---|---|
| AnaemiaBlood and lymphatic system disorders | 193/324 | 180/321 |
| White blood cell count decreasedInvestigations | 143/324 | 157/321 |
| Neutrophil count decreasedInvestigations | 153/324 | 155/321 |
| Decreased appetiteMetabolism and nutrition disorders | 142/324 | 124/321 |
| NauseaGastrointestinal disorders | 122/324 | 136/321 |
| ConstipationGastrointestinal disorders | 102/324 | 101/321 |
| Weight decreasedInvestigations | 97/324 | 91/321 |
| DiarrhoeaGastrointestinal disorders | 88/324 | 76/321 |
| VomitingGastrointestinal disorders | 68/324 | 86/321 |
| HypoalbuminaemiaMetabolism and nutrition disorders | 75/324 | 60/321 |
Intent-to-treat (ITT) analysis set included all randomized participants
| Age, Continuous(years) | Tislelizumab + Chemotherapy | Placebo + Chemotherapy | Total |
|---|---|---|---|
| Median | 64.0 (26 to 84) | 65.0 (40 to 84) | 64.0 (26 to 84) |
| Sex: Female, Male(Participants) | Tislelizumab + Chemotherapy | Placebo + Chemotherapy | Total |
|---|---|---|---|
| Female | 44 | 42 | 86 |
| Male | 282 | 281 | 563 |
| Race (NIH/OMB)(Participants) | Tislelizumab + Chemotherapy | Placebo + Chemotherapy | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 1 | 1 |
| Asian | 243 | 243 | 486 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 79 | 76 | 155 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 4 | 3 | 7 |
| Geographic Region(Participants) | Tislelizumab + Chemotherapy | Placebo + Chemotherapy | Total |
|---|---|---|---|
| Asia (excluding Japan) | 210 | 210 | 420 |
| Japan | 33 | 33 | 66 |
| Rest of World | 83 | 80 | 163 |
| Prior Definitive Therapy(Participants) | Tislelizumab + Chemotherapy | Placebo + Chemotherapy | Total |
|---|---|---|---|
| Yes | 152 | 150 | 302 |
| No | 174 | 173 | 347 |
| Investigator Chosen Chemotherapy(Participants) | Tislelizumab + Chemotherapy | Placebo + Chemotherapy | Total |
|---|---|---|---|
| Platinum with Fluoropyrimidine | 147 | 146 | 293 |
| Platinum with Paclitaxel | 179 | 177 | 356 |
| Programmed Cell Death Protein Ligand-1 (PD-L1) Expression(Participants) | Tislelizumab + Chemotherapy | Placebo + Chemotherapy | Total |
|---|---|---|---|
| PD-L1 Score ≥ 10% | 116 | 107 | 223 |
| PD-L1 Score < 10% | 151 | 168 | 319 |
| Unknown | 59 | 48 | 107 |
Showing the first 100 of 124 sites across 16 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — BeiGene shares data on completed studies responsibly and provides qualified scientific and medical researchers access to data and supporting documentation for clinical trials in dossiers for medicines and indications after submission and approval in the United States, China, and Europe. Clinical trials supporting subsequent local approvals, new indications, or combination products are eligible for sharing once corresponding regulatory approvals are achieved. BeiGene shares data only when permitted by applicable data privacy and security laws and regulations, when it is feasible to do so without compromising the privacy of study participants, and other considerations. Qualified researchers with appropriate competencies who are engaged in novel scientific research may submit a request for participant-level data with a research proposal for BeiGene review. Research teams must include a biostatistician and sign a Data Sharing Agreement prior to receiving access to clinical trial data.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: See plan description
Access criteria: See plan description
Data sharing details ↗ · beigene.com
Ran from Dec 2018 to primary completion in Feb 2022, 38 months.
Results were first posted in Nov 2023, 1 year 8 months after primary completion.
Of 44 phase 3 interventional studies under Esophageal Squamous Cell Carcinoma, half reached primary completion within 66 months of starting (the median), counting those still running; a quarter within 37 and three quarters within 76. This study's 38 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tislelizumab
Esophageal Squamous Cell Carcinoma →